UCB Farchim SA

STI

Pharma

UCB Farchim SA

Member since:

August 2021

UCB is a biopharmaceutical company based in Brussels, Belgium. One of its main drug manufacturing sites is located in Bulle. UCB Switzerland is focused on creating valuable solutions that make improvements to people living with allergies, epilepsy, or autoimmune diseases. At UCB, we see sustainability as a core requirement that lies at the heart of all we do, driving our ambition to make a positive impact on society and the environment while empowering us to ensure UCB long-term success.

Size

250-999

Website

www.ucb.com/

B Corp since

August 2021

Goal 1

Core Business

By 2030, we reduce our water consumption volume by 20 %, compared with 2015.*

* As part of our Health of the Planet program, UCB in Switzerland contributing to UCB Global targets.

Goal 2

Internal Operations

By 2030, we reduce our absolute tCO2eq emissions by 73 % (Scope 1 & 2) compared with 2019, and our tCO2eq target is validated by the Science Based Targets initiative (SBTi) (https://sciencebasedtargets.org/companies-taking-action#table).* * By 2045, we reduce our absolute tCO2eq emissions by 90 % across our entire value chain (Scope 1, 2 & 3) compared with 2019, and neutralise residual emissions. In line with UCB’s global objectives and the ‘Health of the Planet’ programme, UCB in Switzerland is contributing to these collective efforts.

Goal 3

Supply Chain

By 2025, we ensure that over 60 % of all tCO2eq emissions from our suppliers (Scope 3) are covered by the Science Based Targets initiative (SBTi), compared to 23 % in 2021.*

* As part of our responsible procurement initiative, UCB in Switzerland contributing to UCB Global targets, mainly reducing the suppliers’ emissions and compensating the remaining incompressible ones.

Goal 4

Internal Operations

By 2025, we ensure equal opportunities and career development for all our employees, including equal salaries, promotions and individual customized performance reviews.*

* Maintaining the Equal Salary certification, in line with our Diversity, Equity & Inclusion program.

Goal 5

Internal Operations

By 2025, we increase the number of early career profiles (apprentices, interns & graduates) by 30 % compared to 2022, and ensure they get the necessary training and skills to be integrated into the professional world.*

* Carried out by a third party assessment. As part of our Early Careers program, offering free job orientation and personalized support towards our apprenticeship courses. Also further developing collaboration with Swiss universities to create better connectivity with local students and to develop their skills.

Scope of pledges

UCB SA (global group) operates in various markets around the world through a number of subsidiaries and manufacturing sites with clear operational and commercial boundaries. In Switzerland, the company is represented by UCB Farchim SA. The pledges taken within the STI framework relate to the sustainability policy of UCB Farchim SA. The latter is therefore accountable for their implementation within its scope of activity. Where these commitments directly reinforce the Group’s sustainability approach, a special mention is added in the wording. To learn more about the accessibility of our medicines, visit our (Hyperlink: https://reports.ucb.com/ucb-together/together-for-patients/access-to-our-solutions webpage).